The goals of the MAPP Research Network’s first phase (MAPP I) central clinical study – The Trans-MAPP Epidemiology and Phenotyping Study (EPS) – were to gain a better understanding of:
1. How pain and other symptoms are felt in people with Urologic Chronic Pelvic Pain Syndrome (UCPPS) and how they impact overall health;
2. The biological and clinical contributors to symptoms and how these may define distinct UCPPS sub-groups;
3. How UCPPS relates to other common co-occurring chronic overlapping pain conditions (COPCs), such as Fibromyalgia,
Chronic Fatigue Syndrome, or Irritable Bowel Syndrome.
All studies were designed to better understand UCPPS pathophysiology and identify distinct symptom profiles and to inform the design of future, evidence based UCPPS clinical trials for improving clinical management of patients.
The EPS was conducted by six major Discovery Sites, two major Core Sites, and a number of additional integrated research groups:
- Discovery Sites:
- Northwestern University, Chicago, IL
- University of California, Los Angeles, Los Angeles, CA
- University of Iowa, Iowa City, IA
- University of Michigan, Ann Arbor, MI
- University of Washington/Washington State University, Seattle, WA
- Washington University, St. Louis, St. Louis, MO
- Core Sites:
- Data Coordinating Core (DCC): University of Pennsylvania, Philadelphia, PA
- Tissue Analysis and Technology Core (TATC): University of Colorado in Denver, Denver, CO
- Additional, Sub-contracted Research Sites:
- The University of Alabama at Birmingham, Birmingham, AL
- Stanford University, Stanford, CA
- Harvard Medical School/Boston Children’s Hospital, Boston, MA
- Queens University, Kingston Ontario, Canada
- Neuroimaging Core Support Provided by:
- The University of Southern California (USC) Laboratory of Neuroimaging (LONI)
